enGene Holdings Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Selling, General & Admin	19.71	9.6	3.96	3.41	3.24
Research & Development	25.07	16.46	15.47	12.46	10.61
Operating Expenses	44.77	26.06	19.43	15.87	13.85
Operating Income	-44.77	-26.06	-19.43	-15.87	-13.85
Interest Expense / Income	3.89	4.95	1.42	5.02	3.7
Other Expense / Income	64.24	68.89	3.59	2.55	-2.48
Pretax Income	-112.9	-99.9	-24.44	-23.44	-15.07
Income Tax	0.01	0.02	0.02	0	0
Net Income	-112.91	-99.92	-24.46	-23.44	-15.07
Preferred Dividends	2.37	4.82	4.56	-1.19	1.58
Net Income Common	-115.28	-104.74	-29.02	-22.25	-16.65
Shares Outstanding (Basic)	39	1	1	4	3
Shares Outstanding (Diluted)	39	1	1	4	3
Shares Change	5579.47%	5.72%	-81.61%	28.93%	-
EPS (Basic)	-148.05	-151.22	-44.30	-6.25	-6.02
EPS (Diluted)	-148.05	-151.22	-44.30	-6.25	-6.02
Free Cash Flow	-	-25.06	-17.75	-16.23	-13.25
Free Cash Flow Per Share	-	-36.18	-27.09	-4.56	-4.80
EBITDA	-	-94.77	-22.78	-18.17	-11.12
Depreciation & Amortization	-	0.18	0.23	0.25	0.25
EBIT	-109.01	-94.95	-23.02	-18.42	-11.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).